Advarra expands Gene Therapy Ready network with 500+ sites
Posted by Charles Decuir on June 10, 2021 10:55 AM EDT
June 9, 2021 -- Advarra's Gene Therapy Ready network has grown to over 500 registered research sites, making it the largest administrator of institutional biosafety committees (IBCs).
IBCs are responsible for reviewing projects that involve, but are not limited to, recombinant DNA, RNA interference, pathogens, human materials, and other potentially infectious material, as well as transgenic animals, according to guidelines from the U.S. National Institutes of Health (NIH).
The Gene Therapy Ready network is a collective of clinical research sites prepared to conduct trials involving genetically engineered vaccines, gene-modified cellular therapies, and gene therapies. Advarra launched the network in January 2021 with an initial 350 sites.